Medical Devices: Growth Through Acquisitions, US Sales and R&D

Even with slight growth in the market, prospects in medical devices are promising for many firms. More promising than, for example, in the pharmaceutical industry, challenged by patent expirations and regulatory activity. Innovators can still win.  This is the finding of Kalorama Information's yearly study of medical devices.

At a Crossroads, Pharma Clients Seek Flexibility, Efficiency in CRO Market

Kalorama Information also offers the report Proteomics Research Markets: Instruments (Mass Spectrometry, Liquid Chromatography, Electrophoresis), Disease Areas (Oncology, Cardio/Blood, Neurology, Other) Market Share and Trends for market insights into selected products used in biomarker and drug discovery research.

Tracked through seven editions of Kalorama Information’s Outsourcing in Drug Discovery, pharmaceutical research and development (R&D) is now pinned between building market pressures and an explosion in the number of techniques and technological platforms necessary to advance drug candidates. For the first time ever, the global pharmaceutical industry in 2010 cut its R&D budget; subsequent R&D spending growth has been tepid relative to the previous decade with additional industry cuts in 2014 and 2015. With a mantra of “fail early, fail cheaply” for handling high drug candidate attrition rates, pharmaceutical companies are outsourcing increasingly specialized work in drug development, especially as their in-house capabilities have been downsized. In the seventh edition of Outsourcing in Drug Discovery, Kalorama Information analyzes key areas of market growth for contract research organizations (CROs) in terms of services in the drug development process.

Blood Screening Leads Revival of China’s National Blood Program

Investment in screening diagnostics is pivotal in China’s effort to strengthen its scandal-bitten national blood program. Kalorama Information’s recently published Blood Testing Market in China provides IVD-relevant insights into both regional and national demand for blood screening products in China. Blood supply in China is insufficient today to meeting clinical demand in China, but increased donation is being encouraged as blood centers update screening standards and works to improve transfusion safety. Market opportunities for blood screening diagnostics in China relate primarily to blood center upgrading to nucleic acid testing (NAT) methods, expansion of screening capacity, and expansion of the blood supply system to underserved regional markets.

Tags: 

Cepheid, Others Look Beyond Respiratory Infections in the Molecular POC Diagnostics Market

In its most recent earnings call for the first quarter of 2016, Cepheid referenced a conclusion of Kalorama Information's recent report, The Market and Potential for Molecular Point of Care Diagnostics, in outlining its revised short-term market strategy for molecular POC diagnostics. Kalorama’s view, that women’s health testing stands to develop by 2020 into a greater molecular POC market than respiratory infections, resonated with Cepheid as its distributors had also begun to report strong interest at the POC level for associated tests.

Abbott Adds Patient Monitoring Strength With St. Jude Buy

While Abbott's purchase of St. Jude Medical will notably expand Abbott's reach in heart devices, it also places Abbott into patient monitoring. Patient monitoring is one of the fastest growing device areas, with double-digit growth expected the next 5 years, according to Kalorama Information's report, Advanced Remote Patient Monitoring  Abbott Laboratories agreed to acquire St. Jude Medical Inc.

Pages

Subscribe to Kalorama Information Home RSS